237 related articles for article (PubMed ID: 24366192)
1. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
2. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
3. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
Li B; Mascarenhas JO; Rampal RK
Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
[TBL] [Abstract][Full Text] [Related]
4. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
Khan M; Siddiqi R; Gangat N
Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
[TBL] [Abstract][Full Text] [Related]
6. Leukemia secondary to myeloproliferative neoplasms.
Dunbar AJ; Rampal RK; Levine R
Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
[TBL] [Abstract][Full Text] [Related]
7. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
8. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
9. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
10. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms.
Czader M; Orazi A
Am J Clin Pathol; 2015 Aug; 144(2):188-206. PubMed ID: 26185305
[TBL] [Abstract][Full Text] [Related]
11. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
12. Genetics of myeloid malignancies: pathogenetic and clinical implications.
Fröhling S; Scholl C; Gilliland DG; Levine RL
J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
[TBL] [Abstract][Full Text] [Related]
13. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
14. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
[TBL] [Abstract][Full Text] [Related]
16. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
17. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
[TBL] [Abstract][Full Text] [Related]
20. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]